Abstract
The discovery of the ATP-sensitive potassium channel (1) and the knowledge that cellular ATP is decreased in ischemia, has naturally focused attention on the possible role of the ATP-dependent potassium channel in early potassium loss. There is now considerable evidence that the opening of this channel is concerned with the early electrophysiological changes of ischemia, including shortening of the action potential duration and depolarization (2,3). Because these changes are thought to explain ST-segment changes that are diagnostic of exercise-induced angina, (4) it might be supposed that drugs acting as potassium channel openers would only exaggerate potassium loss and worsen ischemia. This point of view fails to recognize that (A) the major effects of the potassium channel openers are probably as vasodilators acting on the coronary vascular tree (5,6) and that (B) the shortening of the action potential duration lias an important anti-ischemic effect, perhaps acting by local cardioplegia and reduced calcium ion entry, thereby decreasing the contractile activity of the ischemic segment and hence “resting” the ischemic myocardium (3,6). Hence the potassium channel openers have potential anti-ischemic and antianginal effects, as will be assessed in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Noma A. ATP-regulated K+ channels in cardiac muscle. Nature 1983; 305: 147–148.
Opie LH. Modulation of ischemia by regulation of the ATP-sensitive potassium channel. Cardiovasc Drugs Ther 1993; 7: 507–513.
Gasser RNA. Klein W. Contractile failure in early myocardial ischemia: Models and mechanisms. Cardiovasc Drugs Ther 1994; 8: 813–822.
Kubota I, Yamaki M, Shibata T, et al. Role of ATP-sensitive K+ channel on ECG ST-segment elevation during a bout of myocardial ischemia. A study on epicardial mapping in dogs. Circulation 1993; 88 [part 1]: 1845–1851.
Hofmann D. Opie LH. Potassium channel blockade and acute myocardial infarction: implications for management of the non-insulin requiring diabetic patient. Editorial. Eur Heart J 1993; 14: 1585–1589.
Yao Z, Gross GJ. Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994: 89: 1769–1775.
Thadani U. Comments on the Food and Drug Administration (FDA) Cardiac and Renal Drugs Advisory Committee Recommended Guidelines for the Conduct of Antianginal Drug Trials. In: Ardissino D, Opie LH, Savonitto S (eds), Drug Evaluation in Angina Pectoris. Kluwer Academic Publishers, Boston. 1994. 251–253.
Dupuis B. European Communities’ Committee for Proprietary Medicinal Products (CPMP) Working Party on Efficacy of Medicinal Products. In: Ardissino D, Opie LH, Savonitto S (eds). Drug Evaluation in Angina Pectoris. Kluwer Academic Publishers. Boston, 1994, 255–258.
Nadazdin A, Davies GJ. Investigation of therapeutic mechanisms of atenolol and diltiazem in patients with variable-threshold angina. Am Heart J 1994; 127: 312–317.
Wiklund I. Quality of life assessments in clinical trials of angina pectoris. In: Ardissino D, Opie LH, Savonitto S (eds), Drug Evaluation in Angina Pectoris. Kluwer Academic Publishers, Boston, 1994, 31–40.
ASIST study (The Atenolol Silent Ischemia Study) - Pepine CJ, Colin PF, Deedwania PC, et al. for the ASIST Study Group. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. Circulation 1994: 90: 762–768.
Brown BG, Lee AB. Bolson ED, Dodge HT. Reflex constriction of significant coronary stenosis as a mechanism contributing to ischemic left ventricular dysfunction during isometric exercise. Circulation 1984; 70: 18–24.
Gage JE, Hess OM, Murakami T, et al. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986; 73: 865–876.
Thaulow E, Guth BD, Ross J Jr. Role of calcium channel blockers in experimental exercise-induced ischemia. Cardiovasc Drugs Ther 1987; 1: 503–512.
Satoh K, Mori T, Yamada H, Taira N. Nicorandil as a nitrate, and cromakalim as a potassium channel opener, dilate isolated porcine large coronary arteries in an agonist-nonselective manner. Cardiovasc Drugs Ther 1993; 7: 691–699.
van Woerkens LJ, Baas NRA, van der Giessen WJ, Verdouw PD. Cardiovascular effects of the novel potassium channel opener bimakalim in conscious pigs after myocardial infarction: A comparative study with nicorandil. Cardiovasc Drugs Ther 1992; 6: 409–417.
Knight C, Purcell H, Fox K. Potassium channel openers: Clinical applications in ischaemic heart disease - Overview of clinical efficacy of nicorandil. Cardiovasc Drugs Ther 1995, in press.
Nakae I, Quan L, Hashimoto K, et al. Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs. Cardiovasc Drugs Ther 1994; 8: 137–145.
Thadani U. Strauss W. Glasser SP. et al. Evaluation of antianginal and anti-ischemic efficacy of nicorandil: Results of a multicenter study (abstr). J Am Coll Cardiol 1994; 24: 267A.
Meany TB, Richardson P, Camm AJ, et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol 1989; 63: 66J-70J.
Kreye VAW, Lenz T, Pfrunder D, Theiss U. Pharmacological characterization of nicorandil by 86Rb efflux and isometric vasorelaxation studies in vascular smooth muscle. J Cardiovasc Pharmacol 1992; 20 (Suppl 3): S8-S12.
Kloner RA, Allen J, Cox TA. et al. Stunned left ventricular myocardium after exercise treadmill testing in coronary artery disease. Am J Cardiol 1991; 68: 329–334.
Vanoverschelde J-L, Wijns W, Depre C, et al. Mechanisms of chronic regional post-ischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993.87: 1513–1523.
Tomai F, Créa F, Gaspardone A, et al. Ischemia preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90: 700–705.
Cavero I. Djellas Y. Guillon J-M. Ischemic myocardial cell protection conferred by the opening of ATP-sensitive potassium channels. Cardiovasc Drugs Ther 1995: 9 (Suppl 2): 245–255.
Gaglione A, Hess OM, Corin WJ, et al. Is there coronary vasoconstriction after intracoronary beta-adrenergic blockade in patients w ith coronary artery disease? J Am Coll Cardiol 1987; 10: 299–310.
Di Somma S, Liguori V, Petitto M, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 1993, 7: 119–123.
Döring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: Results from two multicenter. double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992; 20 (Suppl 3): S74-S81.
Hughes LO. Rose EL, Lahiri A, Raftery EB. Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol 1990; 66: 679–682.
Kinoshita M, Hashimoto K, Ohbayashi Y, et al. Comparison of antianginal activity of nicorandil, propranolol and diltiazem with reference to the antianginal mechanism. Am J Cardiol 1989; 63: 71J-74J.
Meeter K, Kelder JC, Tijssen JGP, et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: A long-term, double-blind, randomized study. J Cardiovasc Pharmacol 1992. 20 (Supp 3): S59-S66.
Ulvenstam G, Diderholm E, Frithz G, et al. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: A double-blind, randomized, multicenter study. J Cardiovasc Pharmacol 1992; 20 (Suppl 3): S67-S73.
Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. Am J Cardiol 1989; 63: 61J-65J.
Kato K, Asanoi H, Wakabayashi C, et al. Effect of nicorandil on exercise performance in patients with effort angina: a multicenter trial using a treadmill exercise test. J Cardiovasc Pharmacol 1987; 10 (Suppl 8): S98-S103.
Silke B, Verma SP, Ali MS, et al. Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induced angina pectoris. Am J Cardiol 1989; 63: 49J-55J.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Kluwer Academic Publishers
About this chapter
Cite this chapter
Opie, L.H. (1995). Is There a Potential Role for KATP Openers in the Treatment of Angina?. In: Yellon, D.M., Gross, G.J. (eds) Myocardial Protection and the KATP Channel. Developments in Cardiovascular Medicine, vol 179. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0453-1_7
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0453-1_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8055-9
Online ISBN: 978-1-4613-0453-1
eBook Packages: Springer Book Archive